194 related articles for article (PubMed ID: 33736679)
1. Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials.
Graeser M; Schrading S; Gluz O; Strobel K; Herzog C; Umutlu L; Frydrychowicz A; Rjosk-Dendorfer D; Würstlein R; Culemann R; Eulenburg C; Adams J; Nitzsche H; Prange A; Kümmel S; Grischke EM; Forstbauer H; Braun M; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
Breast Cancer Res; 2021 Mar; 23(1):36. PubMed ID: 33736679
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
3. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
4. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.
Murphy C; Mukaro V; Tobler R; Asher R; Gibbs E; West L; Giuffre B; Baron-Hay S; Khasraw M
Intern Med J; 2018 Jun; 48(6):699-705. PubMed ID: 28869790
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.
De Los Santos J; Bernreuter W; Keene K; Krontiras H; Carpenter J; Bland K; Cantor A; Forero A
Clin Breast Cancer; 2011 Oct; 11(5):312-9. PubMed ID: 21831721
[TBL] [Abstract][Full Text] [Related]
7. The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrials.
Graeser M; Harbeck N; Gluz O; Würstlein R; Zu Eulenburg C; Schumacher C; Grischke EM; Forstbauer H; Dimpfl M; Braun M; Christgen M; Kreipe HH; Potenberg J; von Schumann R; Aktas B; Kolberg-Liedtke C; Kümmel S; Nitz U
Breast; 2021 Oct; 59():58-66. PubMed ID: 34166854
[TBL] [Abstract][Full Text] [Related]
8. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
9. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
10. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy.
Wang M; Du S; Gao S; Zhao R; Liu S; Jiang W; Peng C; Chai R; Zhang L
Breast Cancer Res; 2024 Feb; 26(1):26. PubMed ID: 38347619
[TBL] [Abstract][Full Text] [Related]
11. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.
Kuzucan A; Chen JH; Bahri S; Mehta RS; Carpenter PM; Fwu PT; Yu HJ; Hsiang DJ; Lane KT; Butler JA; Feig SA; Su MY
Clin Breast Cancer; 2012 Apr; 12(2):110-8. PubMed ID: 22444717
[TBL] [Abstract][Full Text] [Related]
13. Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Graeser M; Schrading S; Gluz O; Strobel K; Würstlein R; Kümmel S; Schumacher C; Grischke EM; Forstbauer H; Braun M; Christgen M; Adams J; Nitzsche H; Just M; Fischer HH; Aktas B; Potenberg J; von Schumann R; Kolberg-Liedtke C; Harbeck N; Kuhl CK; Nitz U
Int J Cancer; 2021 May; 148(10):2614-2627. PubMed ID: 33533487
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
15. Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology.
Chen JH; Bahri S; Mehta RS; Carpenter PM; McLaren CE; Chen WP; Fwu PT; Hsiang DJ; Lane KT; Butler JA; Su MY
J Surg Oncol; 2014 Feb; 109(2):158-67. PubMed ID: 24166728
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
[TBL] [Abstract][Full Text] [Related]
17. Performance of Mid-Treatment Breast Ultrasound and Axillary Ultrasound in Predicting Response to Neoadjuvant Chemotherapy by Breast Cancer Subtype.
Candelaria RP; Bassett RL; Symmans WF; Ramineni M; Moulder SL; Kuerer HM; Thompson AM; Yang WT
Oncologist; 2017 Apr; 22(4):394-401. PubMed ID: 28314842
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy.
Moon HG; Han W; Ahn SK; Cho N; Moon WK; Im SA; Park IA; Noh DY
Ann Surg; 2013 Jan; 257(1):133-7. PubMed ID: 22968080
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC;
Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]